SEARCH:   Advanced

Blood, 1 January 2005, Vol. 105, No. 1, pp. 405-409. Prepublished online as a Blood First Edition Paper on June 10, 2004; DOI 10.1182/blood-2004-03-1103. This Article Full Text Full Text (PDF) All Versions of this Article: 2004-03-1103v1 105/1/405    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Garderet, L. Articles by Frassoni, F. Search for Related Content PubMed PubMed Citation Articles by Garderet, L. Articles by Frassoni, F. Related Collections Neoplasia Transplantation Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  TRANSPLANTATION Hematopoietic stem cell transplantation for de novo acute megakaryocytic leukemia in first complete remission: a retrospective study of the European Group for Blood and Marrow Transplantation (EBMT) Laurent Garderet, Myriam Labopin, Norbert-Claude Gorin, Emmanuelle Polge, André Baruchel, Giovanna Meloni, Juan Ortega, Jaak Vossen, Donald Bunjes, Guy Leverger, Didier Blaise, Augustin Ferrant, Mats Brune, Eric Dore, Helmut Gadner, Felix Zintl, Isaac Yaniv, Giorgio Dini, and Francesco Frassoni From the Acute Leukemia Working Party and the Pediatric Working Party of the European Group for Blood and Marrow Transplantation (EBMT); the Centre International de Greffes, AP-HP, Université Paris VI, Paris; and the Department of Hematology and Cell Therapy, Hôpital Saint Antoine, Paris, France. Acute megakaryoblastic leukemia (M7 AML) is a highly aggressive disease. We evaluated outcomes in 57 children (11 with Down syndrome) and 69 adults with M7 AML after first complete remission (CR1) following autologous or HLA-identical allogeneic transplantation. Characteristics of the recipients of autologous transplants (38 children, 37 adults) were, respectively: median age, 1.7 and 46 years; non-total body irradiation (non-TBI) conditioning regimen, 97% and 70%; bone marrow as stem cell source, 74% and 43%. Characteristics of the recipients of allogeneic transplants (19 children, 32 adults) were, respectively: median age, 2.8 and 37 years; non-TBI regimen, 63% and 42%; bone marrow as stem cell source, 95% and 69%. Autologous transplantation benefited children more; the relapse rate was high in adults. Results for autologous transplantation were (children and adults, respectively): engraftment, 90% and 100%; 3-year treatment-related mortality (TRM) rate, 3% and 8%; relapse rate, 45% and 64%; leukemia-free survival (LFS) rate, 52% and 27%; overall survival (OS) rate, 61% and 30%. After allogeneic transplantation, TRM was fairly low in children and adults, and relapse rates were lower than after autologous transplantation. Results for allogeneic transplantation were, respectively: engraftment, 95% and 90%; TRM, 0% and 26%; relapse rate, 34% and 28%; LFS, 66% and 46%; OS, 82% and 43%). We conclude that M7 AML patients in CR1 (except children with Down syndrome, who already have better outcomes) can benefit from transplantation. (Blood. 2005;105:405-409) CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: Y. Oki, H. M. Kantarjian, X. Zhou, J. Cortes, S. Faderl, S. Verstovsek, S. O'Brien, C. Koller, M. Beran, B. N. Bekele, et al. Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center Blood, February 1, 2006; 107(3): 880 - 884. [Abstract] [Full Text] [PDF]

	Copyright © 2005 by American Society of Hematology         Online ISSN: 1528-0020